biotech · Glioblastoma · Recurrent Brain Metastases · GTBP
GT Biopharma
GT Biopharma clinical programs — 8 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Brisbane, USA
- Founded
- 1973
- Employees
- 8
- Programs
- 8
- Drugs
- 7
- Patents
- 1
GT Biopharma projects
8 ClinicalTrials.gov programs sponsored by GT Biopharma.
GT Biopharma has 8 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Stereotactic Radiation Therapy
GT Biopharma
Brain Metastases
1 trial -
Temozolomide
GT Biopharma
Glioblastoma
1 trial -
Cesium-131 brachytherapy
GT Biopharma
Recurrent Brain Metastases
1 trial -
GTB-3550 TriKE® Phase I
GT Biopharma
High-risk Myelodysplastic Syndromes
1 trial -
GTB-5550
GT Biopharma
Tri-specific Killer Engager
1 trial -
GTM-103
GT Biopharma
Glioblastoma
1 trial -
Stereotactic Radiation Therapy
GT Biopharma
Glioblastoma
1 trial -
Semaglutide
GT Biopharma
Obesity (Disorder)
1 trial
Frequently asked questions
How many clinical projects does GT Biopharma have?
8 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.